Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Brain Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Brain Cancer

Expert Opinion / Cases · May 02, 2022

WHO Grade 2 IDH-Mutant Astrocytoma in a 28-Year-Old Woman

Written by
Martin C. Tom MD


Additional Info

Disclosure statements are available on the authors' profiles:

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • alluru raju

    May 06, 2022

    Focal RT to both the lesions with potons along with Tab Temozolomide , a dose of 54 Gy in 6 weeks

  • Samaneh Sarbaz

    May 06, 2022

    I will radiate the bed of lesions with photon concurrent with TMZ,related to her age and two lesions.5400 cGy

  • aye aye myint

    May 18, 2022

    For remaining left superior frontal lesion about 2.9 cm in GD ,  maximal safe resection can be done if possible.
    For Post operative management of 2 lesions, focal RT with proton.

  • Martin Tom

    May 28, 2022

    The left frontal lesion underwent gross total resection. Pathology was identical to the left parietal lesion indicating a true multicentric grade 2 IDH-mutant astrocytoma. We are advocating for focal proton therapy to both sites with TMZ.

  • Feb 23, 2024

    Pending Moderator approval.

Further Reading